This pooled analysis fills a critical evidence gap for family medicine practice by demonstrating that semaglutide efficacy in weight reduction and metabolic improvement extends reliably to patients over 65, a population historically underrepresented in obesity trials. Since older adults often present with multiple comorbidities where weight loss provides documented cardiovascular and glycemic benefits, having robust efficacy data in this age group removes a key barrier to appropriate GLP-1 prescribing in a substantial portion of the primary care population. The findings support evidence-based treatment decisions in seniors with obesity, enabling clinicians to offer this therapeutic option with confidence rather than defaulting to less effective alternatives due to prior uncertainty about efficacy in older cohorts.

A pooled analysis of trial data examined semaglutide efficacy and safety in patients aged 65 and older with obesity. The analysis consolidated evidence from multiple studies to characterize how this GLP-1 receptor agonist performs in the older adult population, an age group that has been underrepresented in obesity treatment trials. This analysis was undertaken to address the existing knowledge gap regarding GLP-1 receptor agonist use in seniors and to provide clinicians with data specific to this demographic when making treatment decisions.

The analysis demonstrated that older patients with obesity respond favorably to semaglutide treatment. Participants aged 65 and older achieved clinically meaningful weight loss and showed safety profiles consistent with younger populations in the trials. The data support the efficacy of semaglutide across the age spectrum and indicate that advancing age alone should not be a barrier to treatment initiation in appropriate candidates. These findings are particularly relevant given the high prevalence of obesity in older adults and the associated metabolic complications that can benefit from weight loss intervention.

For prescribers, these results provide reassurance that semaglutide can be prescribed to older patients with obesity with expectation of therapeutic benefit and tolerability comparable to younger cohorts. The evidence helps establish that age-related physiologic changes do not substantially impair semaglutide’s mechanism of action or necessitate age-specific dosing modifications in this population. Clinicians can therefore apply the same efficacy-based risk-benefit assessment framework used for younger patients when considering semaglutide for older adults with obesity and appropriate indications.

Pooled trial data demonstrates that semaglutide produces meaningful weight loss in adults over 65 with obesity, closing an important evidence gap for GLP-1 use in older populations. This finding supports prescribing GLP-1 receptor agonists to eligible senior patients rather than withholding them based solely on age. Family physicians can counsel older patients that age alone does not preclude GLP-1 therapy if metabolic and cardiovascular indications are present. When discussing semaglutide with patients 65 and older, frame it as evidence-based rather than experimental, which often increases uptake and medication adherence in this demographic.

“The pooled analysis demonstrating robust semaglutide efficacy in adults over 65 with obesity is clinically meaningful because it directly addresses a population we’ve historically underrepresented in GLP-1 trials. I’ve seen firsthand that older patients often respond as well as or better than their younger counterparts, likely due to improved medication adherence and reduced competing metabolic pressures. When counseling patients in this age group, I now lead with the evidence that age alone should not be a barrier to GLP-1 therapy, while of course maintaining careful attention to renal function, polypharmacy interactions, and individual frailty assessment. This data gives us the confidence to offer these agents to appropriate older adults rather than defaulting to assumption-based hesitancy.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: